Rationale: Innate and adaptive immune responses alter numerous homeostatic processes that are controlled by nuclear hormone receptors. NR4A1 is a nuclear receptor that is induced in vascular pathologies, where it mediates protection.
M embers of the nuclear receptor superfamily of transcription factors control diverse aspects of development, homeostasis and immunity. 1 This diversity of function is exemplified by the NR4A subfamily, consisting of NR4A1, NR4A2, and NR4A3. NR4A2 is required for the development of dopaminergic neurons, 2 and all 3 NR4A proteins regulate aspects of myeloid cell differentiation. [3] [4] [5] [6] [7] Expression levels of NR4A proteins are regulated in muscle and liver by diet 8 and NR4A proteins influence hepatic glucose metabolism. 9 NR4A proteins are also highly inducible in macrophages and other cells types involved in inflammatory responses, 3,5,6,10 -13 suggesting roles in immunity. For example, a recent study identified a critical role for NR4A1 in the differentiation and survival of Ly6C Ϫ monocytes. 7 Endogenous ligands for members of the NR4A subfamily have not been identified, and the transcriptional activities of all 3 family members are thought to be mainly dependent on their expression levels. In addition, corepressors, 14 coactivators [15] [16] [17] [18] [19] and posttranslational modifications 20 -22 modulate the transcriptional activities of NR4A family members. Moreover, specific compounds have recently been identified that can function as transactivators or putative ligands for NR4A nuclear receptors, respectively. 19, [23] [24] [25] We and others have shown that NR4A1 (Nur77, Nak-1, TR3, NGFI-B) is upregulated in the inflamed vasculature, specifically in endothelial cells, smooth muscle cells, and monocytes. 3,10 -12,26 In mice transgenic for a dominant negative form of NR4A1, a significantly higher degree of restenosis has been found in response to carotid artery ligation, indicating a protective role of NR4A1 in this specific model. 27 In human macrophages, NR4A1 has been shown to reduce the expression of proinflammatory genes. 3 In addition, beneficial anti-inflammatory functions of another NR4A family member, NR4A2, have been demonstrated in micro-glia cells and astrocytes, in which NR4A2 was shown to recruit the CoREST corepressor complex, resulting in the clearance of NF-kappaB-p65 and in transcriptional repression of NF-B target genes. 5 On the other hand, others have reported that NR4A1 is upregulated by inflammatory stimuli in a mouse macrophage cell line 12 and that its overexpression induces the expression of inflammatory response genes. 13 Therefore, while there is agreement that NR4A1 is upregulated in vascular pathologies, 10 -12,27 there are conflicting data and hypotheses on its functional role in inflammatory responses. 3, 13, 27, 28 One possible explanation for these observed discrepancies in the function of NR4A1 may be found in the modulatory activity of as yet unidentified factors. We therefore searched for possible modulators of NR4A1 activity that may influence its specific roles in vascular pathologies.
We report the identification of interferon stimulated gene 12 (ISG12, IFI27) as a novel modulator of the activity of NR4A nuclear receptors. Under normal conditions, ISG12 is expressed at low levels in the inner nuclear envelope and is strongly upregulated in response to inflammatory stimuli. We further found that ISG12 Ϫ/Ϫ mice are completely protected from restenosis in vascular injury models, and that this was dependent on the presence of NR4A1. We therefore conclude that ISG12 is upregulated in the vasculature upon injury and contributes to vascular pathologies by affecting transcriptional activities of "protective" nuclear receptors, such as NR4A1. Thus, ISG12 represents a hitherto unidentified layer of regulation for the activity of NR4A nuclear receptors that is highly relevant to vascular diseases and may serve as a potential target for novel therapeutic strategies.
Methods
An expanded Methods section is available in the Data Supplement.
Cell Culture and Transfections
Human umbilical vein endothelial cells (HUVECs) 11 and human umbilical artery smooth muscle cells (HUASMCs) 29 were cultured as previously described and used until the 5 th (HUVECs) or 6 th (HUASMCs) passage, respectively. Expression of the ISG12 and NR4A1 did not change during passaging. U937 cells were cultured as described previously. 30 Mouse microvascular endothelial cells (MVECs) and smooth muscle cells (MVSMCs) were obtained and cultured as described previously. 31 Mouse embryonic fibroblasts (MEFs) from wild-type and ISG12 deficient mice were obtained, culture, and transfected as described previously. 32 HUVECs and MEFs were transfected using Lipofectamine Plus (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. HUASMCs were transfected using SuperFect (QIAGEN, Venlo, The Netherlands) according to the manufacturer's protocol. Human embryonic kidney cells (293 cells) were cultured as recommended (ATCC, Manassas, VA). 293 cells were transiently transfected for luciferase reporter assays, cell fractionation experiments, western blot or microscopy using calcium-phosphate. 33 Organelle lights were transfected according to the manufacturer's instructions (Invitrogen). For siRNA transfection, 293 cells were transfected with polyethylenimine 34 using siRNAs from Ambion (Austin, TX). Efficiency of silencing was evaluated by q-PCR or by Western blot. Transfection mixtures always contained the same amount of DNA, and for cotransfections all vectors were used in equal ratios. In titration experiments, differences in the vector amounts were substituted with corresponding empty vectors.
Plasmids
Human full length ISG12 (AA1-122) was cloned into pCMV-myc (Clontech, Palo Alto, CA). ISG12 promoter luciferase constructs (Ϫ923 to ϩ30, Ϫ730 to ϩ30, Ϫ397 to ϩ30) were cloned into pGL3. Additional ISG12 promoter constructs (deleted or mutated) used in this study were generated using the QuickChange mutagenesis kit (Stratagene, La Jolla, CA) according to manufacturer's protocol. Constructs for full length EGFP-NR4A1 (AA1-598), dominant negative EGFP-NR4A1 (AA248 -580), the luciferase reporter construct 4ϫNBRE, and pcDNA 3.1-NR4A1 (AA 1-598) were previously described. 11 The constructs pXP1-NurRE-luciferase, DR5luciferase, pCMX-NR4A2, and pCMX-NR4A3 were kindly provided by J. Drouin. 35 Flag-CRM1 was a kind gift from W. Wang.
Yeast Library Construction and Yeast-2-Hybrid Screen
In brief, the yeast-2-hybrid screen for interaction partners of NR4A1 was performed using a yeast library generated with cDNA obtained from lipopolysaccharide (LPS)/tumor necrosis factor (TNF)␣-activated human uterine microvascular endothelial cells. Yeast library construction was performed using the MATCHMAKER Library Construction and Screening Kit (Clontech) according to the manufacturer's recommendations. For screening, a construct of NR4A1 coding for amino acids 248 to 557 lacking the transactivation domains 1 and 2 was cloned into pGBKT7.
Immunoprecipitation, Western Blotting, and Chromatin Immunoprecipitation
Protein interactions in transfected 293 cells were determined by immunoprecipitation of transfected or endogenous NR4A1, Lamin A, or ISG12, followed by immunoblotting of coprecipitated interaction partners. Chromatin immunoprecipitation (ChIP) was performed on 293 cells stimulated with or without IFN␣, respectively, using the EZ Chip kit (Upstate Inc). Subsequent PCR analyses were performed by LightCycler technology using the Fast Start SYBR Green I kit (Roche Diagnostics).
Immunocytochemistry and Microscopy
Immunocytochemistry was performed on transfected or not transfected: HUVECs, HUASMCs, 293 cells, or MEFs according to procedures previously described. 36 In addition, the subcellular localization of NR4A1 in arterial cross-sections was also assessed by immunohistochemistry.
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Fluorescence Resonance Energy Transfer
For fluorescence resonance energy transfer (FRET) experiments, cells were cotransfected with myc-ISG12 and an EGFP-NR4A1 construct or with the respective controls. After 24 hours, cells were fixed and processed for immunocytochemical staining of the myc-ISG12 using anti-myc antibody and Alexa 568-conjugated antimouse. A modified version of a method previously reported by König et al 37 was used, in which FRET was assessed between EGFP-labeled NR4A1 and the immune complex of Alexa 568labeled anti-myc antibody and myc-tagged ISG12. Images for FRET were recorded on a confocal microscope (Zeiss LSM510) or an a epiluminescence microscope (Olympus AX-70) and analyzed using ImageJ software with the FRET and colocalization-analyzer plugin. 38
Isolation of Nuclear Fractions and Fractionation of Nuclear Envelopes
Isolation of nuclear extracts was performed as previously described. 39 The presence of NR4A1 and histone H3 was determined in lysed nuclear fractions by immunoblotting and quantified using the Image J1.33u software. Additional isolation of nuclei for further separation of inner and outer nuclear envelopes was done according to Gilchrist and Pierce. 40 
Luciferase Assays
Two-hundred ninety-three cells were transfected as outlined, and cotransfected with pRL-SV40 renilla vector internal transfection efficiency standard. Luciferase and renilla assays were performed 30 hours after transfection using a Dual Luciferase Assay Kit (Promega, Madison, WI) according to the manufacturer's instructions. Luciferase activity was normalized to respective renilla values. All experiments were done in triplicates and repeated at least twice.
RNA Isolation and Quantitative RT-PCR
RNA isolated from pooled mouse arterial tissue (nϭ9) or from HUVECs, HUASMCs, U937 cells, MVSMCs, MVECs, and MEFs (nϭ3 each) was isolated using Trizol, reverse-transcribed, and analyzed by quantitative q-PCR using LightCycler technology (Roche Diagnostics). Expression of target genes (ISG12, NR4A1, and MCP-1) was normalized to the expression of housekeeping gene hydroxymethylbilane synthase (PBGD) or cyclin B.
Generation of ISG12 ؊/؊ and ISG12 ؊/؊ ؋NR4A1 ؊/؊ Mice ISG12 Ϫ/Ϫ mice were generated using previously described procedures. 41 ISG12 Ϫ/Ϫ ϫNR4A1 Ϫ/Ϫ were generated by cross-breeding of ISG12 Ϫ/Ϫ mice with NR4A1 Ϫ/Ϫ mice, which were kindly provided by J. Milbrandt (Washington University, School of Medicine, St Louis, MO). The background of the ISG12 Ϫ/Ϫ mice used for the carotid ligation ( Figure 4B ) and femoral cuff ( Figure 4C ) experiments was 50% 129S/v and 50% Swiss Webster obtained from heterozygous breeding pairs. Wild-type littermates served as controls. For the generation of ISG12 Ϫ/Ϫ ϫNR4A1 Ϫ/Ϫ mice, ISG12 Ϫ/Ϫ mice were bred with NR4A1 Ϫ/Ϫ mice on a C57BL/6 background. These mice had a background of 25% 129S/v, 25% Swiss Webster, and 50% C57BL/6. Again littermates of ISG12 ϩ/Ϫ ϫNR4A1 ϩ/Ϫ breeding pairs were used for the carotid ligation experiments ( Figure 5B ).
Animal Experiments
All animal experiments were approved by the institutional animal experimental committee. For the restenosis mouse model, mice (8 -12 weeks of age) were subjected to carotid artery ligation according to a published procedure. 42 Briefly, the left common carotid artery of ketamine/xylazine-anesthetized mice was ligated near the distal bifurcation. Ten or 21 days after ligation, mice were anesthetized and subsequently perfused with PBS via the heart and both ligated and not ligated carotid arteries were obtained. For the femoral artery cuff model, the right femoral artery was dissected from surrounding tissue and a nonconstrictive polyethylene cuff (PE50, 2.0 mm in length with a 0.965-mm outer and a 0.58-mm inner diameter; Becton Dickinson, San Jose, CA) was placed loosely around the femoral artery. 43 Twenty-eight days after cuff placement, mice were anesthetized and subsequently perfused with PBS via the heart and both femoral arteries were obtained. The respective numbers of mice used are indicated in the respective figure legends.
Morphometric Analysis
Carotid and femoral arteries were fixed with 4% paraformaldehyde, snap-frozen with OCT media, and serial sections (6 m) were obtained either from the site of ligation to the aortic arch or through the entire length of the cuffed femoral artery. Equivalent areas of control carotid or femoral arteries were analyzed in parallel. Sections were stained with hematoxylin/eosin or stained for smooth muscle actin using a specific antibody (clone 1A4-FITC, Sigma, St Louis, MO), and counterstained with 4=,6 diamidino-2-phenylindole (DAPI, Vector Laboratories, Burlingame, CA). For ligated carotid arteries, a standardized reference point was set at which the vessel structure was not distorted by the ligation and where the elastic laminae were intact. Digital images of cross-sections at 0.7 mm, 1.7 mm, and 2.7 mm from the reference point were obtained with an F-View camera on an Olympus AX-70 microscope and analyzed morphometrically using the AnalySiS software package (Soft Imaging System; Muenster, Germany). In the femoral cuff model, 8 equal cross sections were used from each mouse for morphometric analysis. The circumferences of the lumen, internal elastic lamina, and external elastic lamina were measured, and media area, neointimal area, and neointima/media ratios were calculated as described previously for a rabbit restenosis model. 44
Statistical Analysis
Experimental values are expressed as meanϮSEM if not otherwise indicated. Statistical significances were determined by unpaired Student t test or 1-way ANOVA followed by Bonferroni multiple comparison tests, as indicated. The significance of differences in morphometric analyses in Figures 4 and 5 were determined using the nonparametric Kruskal-Wallis test followed by Dunn multiple comparison tests.
Results

The Interferon Stimulated Gene 12 Interacts With NR4A1
We and others could show that NR4A1 is highly induced by proinflammatory stimuli. 11 Moreover, we have previously demonstrated that TNF␣ is a potent inducer of NR4A1 expression in endothelial cells, which resulted in increased Circulation Research April 13, 2012
PAI-1 expression. To identify binding partners of NR4A1 in vascular cells we screened a cDNA library generated from TNF␣/LPS activated microvascular endothelial cells employing a yeast two hybrid system. 45, 46 Using a truncated NR4A1 (amino acids (AA) 248 -557) as bait, we identified the interferon stimulated gene 12 (ISG12, GI: 55925613) as a novel interaction partner of NR4A1. Direct interaction of NR4A1 with ISG12 was confirmed in yeast by "backtransformation" (Online Figure I, A) . The interaction of NR4A1 and ISG12 in mammalian cells was shown by coimmunoprecipitation of NR4A1 and ISG12. Using an antibody against NR4A1 that precipitated endogenous (Figure 1A , row 2, lane 1) and overexpressed full-length NR4A1 ( Figure 1A , row 2, lane 2) in human embryonic kidney 293 cells, we could show that it coprecipitated overexpressed myc-tagged ISG12 ( Figure 1A , row 1, lanes 1 and 2). In a reverse coimmunoprecipitation using an anti-ISG12 antibody, endogenous ( Figure 1A , row 4, lane 1) and overexpressed NR4A1 ( Figure 1A , row 4, lane 2) was precipitated by ISG12. Moreover, FRET analysis of the interaction between myc-ISG12 and NR4A1 demonstrated the specific interaction between these 2 molecules ( Figure 1B) . FRET image analysis further suggested colocalization of NR4A1 and ISG12 in the area of the nuclear envelope ( Figure 1B , lower panel, blue images). Although NR4A1 has many cellular functions, it mainly acts as a transcriptional factor. Therefore, we wanted to see if the interaction with ISG12 might modulate its transcriptional activity. For this purpose we employed a luciferase reporter system consisting of a quadruplicated NGFI-B response element (NBRE) with binding sites for monomeric NR4A1 and analyzed transcriptional activities of NR4A1 in the presence and absence of cotransfected myc-ISG12 ( Figure  1C ). Overexpression of NR4A1 increased the reporter gene activity more than 10-fold, and this was significantly reduced by Ϸ50% in the presence of coexpressed ISG12. This effect was directly dependent on the amount of ISG12 transfected as shown by the dose response of ISG12 inhibition ( Figure 1D ). Furthermore, the fact that this inhibition reached saturation at a 1:20 ratio suggested that the ISG12-mediated effect is limited, possibly by components of the nuclear pore complex as previously hypothesized. 47 NR4A1 is a member of the NR4A family of nuclear receptors (NR4A1, NR4A2, and NR4A3) that are highly homologous in structure and function. Three different consensus binding sites exist for NR4A family members: NBRE represent binding sites for monomeric binding, Nurresponsive element (NurRE) represents binding sites for homodimeric and heterodimeric binding of all 3 members of the NR4A family, and DR5 is a binding site for NR4A1 or NR4A2 heterodimerized to the retinoic acid receptor RXR. 35 To gain more insight into the functional consequences of the interaction between ISG12 and NR4A1, we analyzed transcriptional activities of all members of the NR4A family in the absence and presence of overexpressed ISG12 using reporter assays for the 3 different consensus binding sites ( Figure 1E through 1G ). Overexpression of ISG12 significantly reduced transcriptional activities of NR4A1 and NR4A2 on all 3 different reporter constructs (NR4A1 and NR4A2 were downregulated by ISG12 on NBRE by 54.6Ϯ4.9% and 30.9Ϯ11.3%; on NuRE by 83.9Ϯ1.2% and 87.1Ϯ0.61%; and on DR5 by 63.5Ϯ1.8% and 54.5Ϯ3.3%, respectively). In contrast, ISG12 overexpression only downregulated NR4A3 activity on NuRE (by 39.1Ϯ4.8%) ( Figure  1F ), but not on NBRE ( Figure 1E ). As expected NR4A3, which does not form heterodimers with RXR, did not transactivate the DR5 reporter construct ( Figure 1G ). From these data, we conclude that ISG12 displays some selectivity within the NR4A family and predominantly downregulates the activities of NR4A1 and NR4A2.
To see whether the effect of ISG12 on transcriptional activity of NR4A1 is influenced by small coactivator molecules ("ligands") that have been shown to induce NR4A1 activity, we performed luciferase reporter assays in the absence or presence of 6-mercapto purine or 9-cis-retinoic acid (9-cis-RA). The increased reporter activity induced by NR4A1 was significantly reduced in the presence of ISG12 independently of the presence of any of the added compounds ( Figure 1H ), suggesting this effect to be independent of these "ligands."
Because the newly discovered activity of ISG12 was reminiscent of nuclear corepressors and most activity of corepressor complexes requires histone deactelyation, we tested whether ISG12 also mediates its effects via histone modification. We therefore studied if the inhibitory effect of ISG12 is still observed in the presence of the histone deacetylase (HDAC) inhibitor Trichostatine A. In luciferase reporter assays, Trichostatine A treatment did not influence the effect of ISG12 on NR4A1 transcriptional activity, whereas-as expected-it increased the activity of NR4A1 on NBRE when ISG12 was not cotransfected ( Figure 1I ). Thus, ISG12 mediates its inhibitory effects via a mechanism that is independent of HDAC activity.
The Inner Nuclear Envelope Protein ISG12 Decreases Transcriptional Activity of NR4A1 by Modulating Its Nucleo-Cytoplasmic Shuttling in a Crm1-Dependent Manner
Because ISG12-mediated repression is independent of nuclear corepressor complexes that recruit HDAC and require HDAC activity, we wanted to determine the mechanisms by which ISG12 decreases NR4A1 transcriptional activity. Figure 2 (Continued) . E, ISG12 mediates the interaction of NR4A1 with Crm1; 293 cells were transfected with scrambled control siRNA or with siISG12 and cotransfected with flag-Crm1 and/or NR4A1, as indicated. Cell lysates were immunoprecipitated using an anti-NR4A1 antibody (rows 1-3), and the presence of NR4A1 and flag-Crm1 was detected by immunoblotting using an anti-NR4A1 (WB1) or an anti-flag antibody (WB2), respectively. Rabbit IgG (WB3) and actin (WB4) were detected as respective loading controls using specific antibodies. Shown is a representative example of 3 independent experiments. WCL indicates whole-cell lysate. F, The ISG12 effect on transcriptional activity of NR4A1 is independent of RXR␣; 293 cells were transfected with siRXR␣ or a scrambled control, as indicated. Subsequently, all cells were transfected with 4ϫNBRE and cotransfected with indicated constructs. Transcriptional activity was assessed in a dual luciferase reporter assay. Data represent meanϮSEM of fold induction above control (nϭ3).
Figure 3. Interferons induce ISG12 expression in vascular cells. A, Interferons induce ISG12 expression in HUVECs.
HUVECs were treated for the indicated time with 100 U/mL TNF␣, 10 g/mL LPS, 1000 U/mL IFN␣, or 100 ng/mL IFN␥, and the expression of ISG12 was analyzed by q-PCR. Data represent meanϮSEM fold expression of ISG12 above control treated cells. B, IFN␣ stimulates expression of ISG12 in vascular cells. Human aortic smooth muscle cells (HUASMCs) and the monocytic cell line U937 were stimulated with 1000 U/mL IFN␣ for 7.5 hours, and ISG12 expression was analyzed by q-PCR. Data represent meanϮSEM fold expression of ISG12 above control treated cells. C, Schematic map of the ISG12 promoter fragments as cloned into the pGL3 vector. Indicated are possible IREs that are binding sites for IRFs. D, IFN␣ regulates ISG12 expression by the proximal promoter 150bp upstream of the transcriptional start site; 293 cells were transfected with ISG12 promoter fragments that differ in lengths and carry either mutations or deletions of the IRE core sequences, respectively. The 5ЈGAAA3Ј core sequence was either mutated to 5ЈTAAT3Ј indicated as m or entirely deleted indicated by d (see schematic representation). Subsequently, cells were treated with 1000 U/mL IFN␣ for 8 hours. Transcriptional activity was assessed with a dual luciferase reporter assay. Data represent meanϮSEM of fold induction of IFN␣ stimulation normalized to respective unstimulated controls (nϭ3). E, Interferon regulatory factors (IRF)-1, -3, and -4 bind to the ISG12 promoter on IFN␣ stimulation. 293 cells were treated with IFN␣ (1000 U/mL, 5 hours), and chromatin immunoprecipitation assays were performed e56
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Therefore, we first analyzed the intracellular distribution of ISG12.
Previously, ISG12 was identified as a nuclear envelope protein, but recently 2 studies reported a mitochondrial localization of ISG12 in 3T3-L1 and fibrosarcoma cells. To identify the subcellular localization of ISG12 in our experimental settings, 293 cells were transfected with myc-ISG12 and its localization was assessed in association with fluorescent markers specific for different organelles (Organelle lights) by fluorescent microscopy (Online Figure I, B ). ISG12 (red in rows 1 and 2, green in row 3) was found to be distributed in the nuclear membrane (green) and in the endoplasmic reticulum (green), and there was no colocalization with mitochondria (red). In addition, we could demonstrate the localization of ISG12 to the nuclear envelope and endoplasmic reticulum in HUASMCs and HUVECs (Online Figure I , C through F). This data supported the data obtained in 293 cells. Furthermore we were able to confirm the nuclear localization of ISG12 by electron microscopy, which revealed a close association of ISG12 with nuclear pores (Online Figure I , G). Moreover, even after Triton X-100 preextraction of cultured cells, which has previously been shown to conserve only perinuclear proteins, 48 ISG12 staining was preserved, further identifying it as a nuclear envelope protein (Online Figure I, H) , as previously shown by Martensen. 47 Cellular fractionation experiments of ISG12 transfected 293 cells further demonstrated the localization of ISG12 to the nuclear envelope (Online Figure  II, A through E).
Because the majority of inner nuclear envelope proteins interact with nuclear scaffold proteins such as lamins to tightly anchor the lamina to the inner nuclear membrane, 49 we tested whether ISG12 had the ability to interact with lamins, such as Lamin A. Indeed, we could confirm the interaction between Lamin A and myc-ISG12 by coimmunoprecipitation using an anti-Lamin A antibody in lysates from 293 cells overexpressing ISG12 (Online Figure II, F, row 2, lane 2) . Thus, we identified ISG12 as a novel interaction partner of NR4A1 and demonstrated its localization at the inner nuclear membrane, where it interacts with proteins of the lamin matrix, such as Lamin A. Therefore, we asked whether ISG12 mediates its effects by physically limiting the presence of NR4A1 in the nucleus. Under normal unstimulated conditions NR4A1 is predominantly localized to the nucleus of HUASMCs and HUVECs (Figure 2A and 2B ). To answer whether the intracellular localization of NR4A1 is affected by ISG12, we studied the change in subcellular distribution of overexpressed EGFP-NR4A1 in the absence or presence of ISG12 by immunofluorescence cytochemistry. While a majority of transfected EGFP-tagged NR4A1 is found in the nucleus ( Figure 2C, row 1, left panel) , part of it is relocated to the cytoplasm when ISG12 is coexpressed ( Figure 2C, row  1, middle and right panel) . In fact, overexpression of ISG12 in HUVEC reduced the nuclear localization of transfected NR4A1 by Ϸ50% ( Figure 2C, row 1, right graph) . Importantly, when the same experiments were performed using an NR4A1 construct (AA 248 -580) that cannot be exported from the nucleus, 50 no influence of ISG12 on the subcellular distribution of that construct was seen ( Figure 2C, row 2) . This indicates that the ISG12 affects the nuclear/cytoplasmic distribution of NR4A1 by modulation of its nuclear export rather than having an effect on its nuclear import. Previously, it has been reported that NR4A1 export is Crm1 dependent. To analyze whether the ISG12-mediated export of NR4A1 is Crm1 dependent as well, we repeated the same experiments as shown in Figure 2C (row 1) but in the presence of the Crm1 inhibitor Leptomycin B. Leptomycin B blocked nuclear export of NR4A1 in the absence as well as in the presence of ISG12, as in both instances nuclear localization of NR4A1 was Ͼ70% ( Figure 2C, row 3, right graph) . This indicates that the basal 50,51 as well as ISG12 enhanced nuclear export of NR4A1 is Crm1 dependent. To quantify the effect of ISG12 on the cellular localization of NR4A1 using a different method, we determined the distribution of NR4A1 between the cytoplasm and the nucleus by analyzing nuclear fractions of cells in which EGFP-tagged NR4A1 was overexpressed in the absence or presence of myc-tagged ISG12 by Western blot (Figure 2D ). In the presence of overexpressed ISG12, the amount of nuclear NR4A1 was decreased by 44.4Ϯ12.9% ( Figure 2D, right graph) , which compares well with the Ϸ50% reduction in nuclear localization as demonstrated by immunocytochemistry.
To further elucidate the mechanism by which ISG12 mediates the nuclear export of NR4A1 in Crm1-dependent manner, we performed coimmunoprecipitation experiments using cell lysates of 293 cells in which ISG12 was silenced and that were transfected with NR4A1 and/or flag-Crm1. As shown in Figure 2E , immunoprecipitation of endogenous and overexpressed NR4A1 results in the coprecipitation of Crm1. However, in cells in which ISG12 was silenced, the amount of Crm1 immunoprecipitated with NR4A1 was clearly reduced compared with cells transfected with scrambled siRNA. Thus, the formation of NR4A1/Crm1 complexes depends partially on the presence of ISG12.
Some investigators suggested that the nuclear export of NR4A1 is dependent on RXR␣ 50,51 and its nuclear export sequence, whereas others have shown a reciprocal model in which RXR␣ export is dependent on NR4A1. 52 To clarify this, we preformed luciferase reporter assays for NR4A1 activity in the presence of overexpressed ISG12 in cells in which RXR␣ was silenced. The efficiency of the siRNA knockdown was confirmed by q-PCR and Western blot analysis (Online Figure II, G and H) . These experiments demonstrated that RXR␣ had no effect on the capacity of Figure 3 (Continued) . using antibodies against IRF-1, IRF-3, and IRF-4 followed by q-PCR using primers specific for the ISG12 promoter. Shown are representative examples of images from agarose gels of q-PCR products from 2 independent experiments. F, IFN␣mediated effects on NR4A1 transcriptional activity are dependent on ISG12. 293 cells were transfected with siISG12 or scrambled control, and cotransfected with a 4ϫNBRE and/or NR4A1 and/or ISG12, as indicated. Subsequently, cells were stimulated with 1000 U/mL IFN␣ for 16 hours, and transcriptional activity was assessed in a dual luciferase reporter assay. Data represent meanϮSEM of fold induction above control (nϭ3).
ISG12 to downregulate NR4A1 transcriptional activity, indicating RXR␣ independence of this mechanism ( Figure 2F ). Therefore, our findings identify ISG12 as a novel interaction partner of NR4A1 that is localized at the inner nuclear envelope (Online Figures I and II) , where it interacts with proteins of the nuclear lamina (Online Figure II, F) and decreases transcriptional activity by influencing the nuclear localization of the orphan nuclear receptor NR4A1 in a Crm1-dependent and RXR␣-independent manner (Figure 2E and 2F ).
ISG12 Is Induced by Interferons in Vascular Cells
Because ISG12 was identified in a cDNA library of endothelial cells treated with TNF␣ and LPS, we first determined its expression in vascular cells in response to various inflammatory stimuli. HUVECs were treated with cytokines and LPS, for various time points and analyzed by q-PCR. As shown in Figure 3A , the known potent ISG12 regulating cytokines interferon-alpha (IFN␣) and interferon gamma (IFN␥) 53 significantly upregulated ISG12 expression after 3.5 hours. We further analyzed the effect of IFN␣ on the expression of ISG12 in other vascular cells, and found that after 7.5 hours ISG12 was upregulated Ϸ20-fold in vascular smooth muscle cells (HUASMCs) and Ϸ25-fold in the monocytic U937 cell line ( Figure 3B ). Similar effects were seen with IFN␥ (data not shown). Moreover, IFN␣-induced expression of ISG12 was also observed in 293 cells and MEFs, murine microvascular endothelial cells (MVECs), and murine MVSMCs (Online Figure III, A through D) . To further elucidate the mechanism by which IFNs induce upregulation of ISG12, we performed in silico analyses of the 1000 bp fragment upstream of the transcriptional start site of ISG12 to include the entire possible proximal promoter region. This analysis revealed 4 potential interferon response elements (IRE; Figure  3C ) containing a conserved sequence (5Ј-GAAA-3Ј) that corresponds to potential binding sites for interferon response factor (IRF)-1, IRF-3, and IRF-4. IRF-4 at Ϫ147 and IRF-3 at Ϫ141 share the same core sequence and therefore cannot be bound simultaneously. To verify the importance of these binding sites for the transcriptional regulation of ISG12, we performed luciferase reporter assays in cells transfected with a reporter construct containing the full length sequence or various fragments of the putative ISG12 promoter in which the potential IREs were mutated or deleted as indicated in Figure 3D . Thereby, we could demonstrate that ISG12 transcription in response to IFN␣ is dependent on the presence of either IRE4 (bp-147) or IRE3 (bp-141) and IRE1 (bp-125), as the deletion/mutation of the binding sites at bp-147 or bp-125 resulted in a complete loss of transcriptional induction on IFN␣ stimulation ( Figure 3D ). Thus, the major regulating effect of IFN␣ was observed in the proximal promoter region of ISG12. Consistent with the importance of this region, ChIP analyses of 293 cell lysates using antibodies against IRF-1, IRF-3, and IRF-4 showed increased binding of these transcription factors to the proximal part of the ISG12 promoter (Ϫ147 bp) in response to IFN␣ stimulation ( Figure  3E ). Therefore, IFN␣ regulation of ISG12 requires binding sites for IRF-1, -3, and -4.
Because we have shown that IFN␣ is the major inducer of ISG12 ( Figure 3A-B and Online Figure III, A through D) , we tested if endogenous ISG12 induced by IFN␣ would also decrease NR4A1 transcriptional activity. Therefore, we performed NBRE luciferase reporter assays following stimulation with IFN␣ in cells, in which ISG12 expression was silenced by siRNA. The efficiency of the siRNA knockdown was confirmed by q-PCR (Online Figure III, E) . As predicted, IFN␣ stimulation decreased the transcriptional activity of NR4A1 in cells transfected with scrambled siRNA, while this effect was lost when ISG12 was silenced ( Figure 3F ). In addition, IFN␣ decreased the transcriptional activity on the NR4A1 response elements, NurRE and DR5 (Online Figure III, G and H) . Thus, IFN␣ decreases NR4A1 transcriptional activity and this effect is mediated through the presence of ISG12.
Furthermore, IFN␥, which activates ISG12 as potently as IFN␣, was also found to downregulate the transcriptional activity of NR4A1 (Online Figure III, F) .
Generation of ISG12-Deficient Mice
To obtain insight into the function of ISG12 in vivo, we generated ISG12 Ϫ/Ϫ mice by targeted gene disruption as outlined in Online Figure IV , A. 41 Successful gene deletion was confirmed by Southern blot analyses as well as by PCR for ISG12 in the spleens isolated from these mice (Online Figure IV , B and C). Male and female ISG12 Ϫ/Ϫ mice exhibited no obvious gross phenotypic pathologies, having normal growth rates, survival, fertility, and litter sizes (data not shown). Routine histological analysis did not reveal any signs of organ pathology.
ISG12 Deficiency Protects From Vascular Injury In Vivo
To study the significance of ISG12 in vascular pathology, we tested its role in vascular injury using a carotid artery ligation model 42, 54 and a femoral artery cuff model. 43, 55, 56 ISG12 is also potently induced by IFN␣ in both murine SMC and ECs (Online Figure III , C and D). We first determined the expression of ISG12 in response to carotid artery ligation in wild-type mice. Three weeks after ligation the expression of ISG12 was highly upregulated in the ligated arteries when compared with the contralateral unligated arteries ( Figure 4A) . Similarly, NR4A1, which has been shown to mediate protection in the same model, 27 as well as the inflammatory marker gene monocyte chemoattractant protein-1 (MCP-1), which has been implicated in restenosis, 44 were also found significantly upregulated in ligated carotid arteries of wild-type mice ( Figure 4A ). In ligated arteries of ISG12 Ϫ/Ϫ mice, there was a similar upregulation of NR4A1 resulting in comparable levels as in wild-type mice, while upregulation of MCP-1 was absent, indicating a reduced inflammatory response (data not shown). We then used the carotid artery ligation model to determine the effect of ISG12 gene inactivation on neointima formation. As shown in Figure  4B , ligated carotid arteries of ISG12 Ϫ/Ϫ mice retained a significantly larger lumen area than wild-type litter mates indicating a critical role for ISG12 in the vascular response to injury. In fact, ISG12 Ϫ/Ϫ mice exhibited only negligible neointima formation as compared with wild-type mice while the vessel diameter (circumference of the external elastic lamina, EEL) was unaffected. Moreover, we observed no morphological differences between wild-type and ISG12 Ϫ/Ϫ mice in unligated control carotid arteries, indicating that the absence of ISG12 does not influence vascular morphology under basal conditions where ISG12 is expressed only at low levels. In vascular injury (ligation), however, ISG12 is highly upregulated ( Figure 4A ) and is associated with increased neointima formation ( Figure  4B ). To demonstrate that the beneficial effect of ISG12 deficiency is not restricted to the specific model used, we employed the femoral artery cuff model ( Figure 4C) . Also in this model neointima formation in the ISG12 Ϫ/Ϫ mice was less than 20% of that in wild-type mice. Based on this protective effect of ISG12 deficiency, our results suggest that ISG12 promotes neointima formation in response to vascular injury.
Based on our insights gained above, we hypothesized that the protective mechanism of ISG12 deficiency is mediated by the transcriptional activity of NR4A1. Indeed, using MEFs transfected with EGFP-NR4A1, we demonstrated by immu- nocytochemistry that IFN␣ stimulates the nuclear export of NR4A1 in wild-type but not ISG12 Ϫ/Ϫ cells ( Figure 4D ). In fact, IFN␣ treatment reduced nuclear localization of NR4A1 significantly by Ϸ40% only in wild-type but not in ISG12 Ϫ/Ϫ MEFs. Moreover, we analyzed the presence of NR4A1 in the nuclei of cells in the vascular wall of ligated and nonligated carotid arteries of wild-type and ISG12 deficient mice 10 days after ligation ( Figure 5A ). In cells of the vascular wall of ligated arteries of wild-type mice only 5.6Ϯ0.5% of NR4A1 was located in the nuclei, whereas in cells of ISG12 Ϫ/Ϫ mice, 10.0Ϯ0.7% of total NR4A1 was found in the nucleus ( Figure  5A ). In contrast, in control arteries no difference in the nuclear localization of NR4A1 was found between wild-type (5.9Ϯ0.7%) and ISG12 Ϫ/Ϫ (6.5Ϯ0.5%) mice, indicating that only on injury when ISG12 is upregulated, the relative distribution of NR4A1 within the cell is affected. Thus, ISG12 mediates nuclear export of NR4A1, but only when induced by appropriate stimuli, such as vascular injury or IFN␣.
To finally prove that the protective effect of ISG12 deficiency is really dependent on the presence of NR4A1, we generated ISG12ϫNR4A1 double knockout mice by intercrossing ISG12 Ϫ/Ϫ mice with NR4A1 Ϫ/Ϫ mice. 57, 58 We then subjected the resulting double-deficient mice and indicated littermate controls to carotid artery ligation. As expected, ISG12 deficiency was protective against restenosis also in these mice, confirming our previous results. No additional increase of restenosis was observed in NR4A1 Ϫ/Ϫ mice compared with wild-type mice, probably because maximum restenosis was already achieved in wild-type mice in this experimental set up. Importantly, ISG12ϫNR4A1 doubledeficient littermates exhibited substantial restenosis similar to wild-type littermates ( Figure 5B ). Therefore, additional NR4A1 deficiency reversed the beneficial effect of ISG12 deficiency, indicating that the protective character of ISG12 deficiency is dependent on the presence of NR4A1.
Discussion
The vascular response to injury is a process that is involved in many vascular pathologies including atherosclerosis and restenosis. We here describe ISG12 as a novel modulator of the vascular response to injury. ISG12 is a member of a family of small interferon stimulated genes 59 that are upregulated in cells on stimulation by interferon, 53,60 but its function was so far unknown. In this report, we describe a molecular function for this gene and its role in vascular pathology.
We observed that ISG12 is upregulated at the site of vascular injury and influences activities of nuclear receptors including NR4A1 and NR4A2, thereby reducing their beneficial effects. 27 This could explain why the naturally occurring upregulation of NR4A1 at sites of vascular injury 3, 11 cannot fully display its previously reported beneficial activities on restenosis. 27 When ISG12 Ϫ/Ϫ mice were analyzed for their susceptibility to develop vascular pathologies, we found that ISG12 Ϫ/Ϫ mice were resistant to neointima formation after carotid artery ligation and in the femoral artery cuff model. However, when ISG12ϫNR4A1double-deficient mice underwent carotid artery ligation, the degree of reste- Figure 5 . The vasculoprotective effect of ISG12 deficiency depends on NR4A1. A, The nuclear localization of NR4A1 is increased in the vessel walls of ligated carotid arteries of ISG12 Ϫ/Ϫ mice. Sections of ligated carotid arteries of ISG12 Ϫ/Ϫ and wt mice were stained with anti-NR4A1 antibodies (green) and nuclei were counterstained with propidium iodide (PI) (red). The images on the left show the bordered area that is enlarged in the images on the right. The yellow color indicates localization of NR4A1 in the nucleus. The quantification is shown in the graph. Data indicated are given as box plots of the percentage of NR4A1 that colocalize with the nuclear staining (median, 25 th and 75 th percentiles, and range) (nϭ4ϫ500 cells). B, Neointima formation was assessed by carotid artery ligation in wt, ISG12 Ϫ/Ϫ , NR4A1 Ϫ/Ϫ , and NR4A1 Ϫ/Ϫ ϫISG12 Ϫ/Ϫ mice (7 mice per group). Representative images of control and ligated carotid artery sections from wt, ISG12 Ϫ/Ϫ , NR4A1 Ϫ/Ϫ , and NR4A1 Ϫ/Ϫ ϫISG12 Ϫ/Ϫ mice stained with hematoxylin/eosin. Quantification of the intima/media ratio in ligated carotid arteries from wt, ISG12 Ϫ/Ϫ , NR4A1 Ϫ/Ϫ , and NR4A1 Ϫ/Ϫ ϫISG12 Ϫ/Ϫ mice.
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nosis was not different from wild-type mice, indicating that the protective effect of ISG12 deficiency in carotid artery ligation is dependent on the presence of NR4A1. Although we cannot exclude a contribution of other members of the NR4A 27 family, the major functional target for ISG12 in this model of restenosis is NR4A1, as the beneficial effect of ISG12 deficiency was completely reversed by additional deficiency of NR4A1. In addition, we identified a molecular mechanism by which ISG12 influences NR4A1 transcriptional activity ( Figure 6 ). We demonstrate that ISG12, localized in the inner nuclear membrane, promotes the nuclear export of NR4A1, thereby decreasing its nuclear localization and capability to transactivate. Thus ISG12 serves as a docking site which sequesters NR4A1 in the nuclear envelope. This interaction may result in a conformational change of NR4A1 that then exposes its nuclear export sequences (NES) on the surface of the molecule. Exposed NES recruit Crm1, which detaches itself and mediates the export of NR4A1 as a cargo to the cytoplasm through nuclear pores. Therefore inflammatory upregulation of ISG12 increases nuclear export of NR4A1, thereby decreasing its transcriptional activity. In this regard ISG12 represents a novel mechanism by which inflammation modulates the activities of nuclear receptors in vascular pathologies.
The recent findings that NR4A1 inhibits the development of atherosclerosis in mice 61,62 points to another important vascular pathology that could be modulated by ISG12. Future experiments will aim at identifying the role of ISG12 in atherosclerosis and elucidate whether these effects are mediated through the ability of NR4A1 to control proinflammatory monocytes and/or macrophages, respectively.
In summary, our data indicate that ISG12 is a novel gene upregulated in the vasculature on injury, which contributes to vascular pathologies. This is mediated by increasing nuclear export of nuclear receptors, thereby downregulating their transcriptional activities. ISG12 therefore represents a target for novel therapeutic strategies for the treatment of vascular diseases. There ISG12 serves as a docking site for NR4A1 and Crm1, which mediates nuclear export of NR4A1 into the cytoplasm. Therefore, the availability of NR4A1 to bind DNA and activate transcription is decreased in the nucleus. NPC indicates nuclear pore complex.
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